Current pharmacotherapy of nocturia

Bibliography

• Staskin DR, Kelleher C, Bosch R, Initial assessment of urinary and faecal incontinence in adult male and female patients. In: Abrams P, Cardozo L, Khoury S, Wein AJ, editor. Incontinence. 4th edition. Health Publications Ltd, Paris; Editions 21 2009. p. 331-412
   Google Scholar
• Payne C, Brown J, Castro D, Research. In: Abrams P, Cardozo L, Khoury S, Wein AJ, editor. Incontinence. Health Publications Ltd, Paris; Editions 21 2009. p. 1713-66
   Google Scholar
• Weiss JP, Wein AJ, van Kerrebroeck P, Nocturia: new directions. Neurourol Urodyn 2011;30:700-3
   PubMed Web of Science ®Google Scholar
• Weiss JP, Blavas JG. Nocturnal polyuria vs. overactive bladder in nocturia. Urology 2002;60:28-32. discussion
   PubMed Web of Science ®Google Scholar
• van Kerrebroeck P, Abrams P, Chaikin D, The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:179-83
   PubMed Web of Science ®Google Scholar
• Gulur DM, Mevcha AM, Drake MJ. Nocturia as a manifestation of systemic disease. BJU Int 2011;107:702-13
   PubMed Web of Science ®Google Scholar
• Weiss JP, van Kerrebroeck PE, Klein BM, Excessive nocturnal urine production is a major contributing factor to the etiology of nocturia. J Urol 2011;186:1358-63
   PubMed Web of Science ®Google Scholar
• Weiss JP. Nocturia: "do the math". J Urol 2006;175:S16-18
   PubMed Web of Science ®Google Scholar
• Yalkut D, Lee LY, Grider J, Mechanism of atrial natriuretic peptide release with increased inspiratory resistance. J Lab Clin Med 1996;128:322-8
   PubMed Web of Science ®Google Scholar
• Hakkinen JT, Shiri R, Koskimaki J, Depressive symptoms increase the incidence of nocturia: tampere Aging Male Urologic Study (TAMUS). J Urol 2008;179:1897-901
   PubMed Web of Science ®Google Scholar
• Asplund R, Henriksson S, Johansson S, Nocturia and depression. BJU Int 2004;93:1253-6
   PubMed Web of Science ®Google Scholar
• Smith AL, Wein AJ. Outcomes of pharmacological management of nocturia with non-antidiuretic agents: does statistically significant equal clinically significant? BJU Int 2011;107:1550-4
   PubMed Web of Science ®Google Scholar
• Lose G, Lalos O, Freeman RM, Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double bland placebo-controlled study in women. Am J Obstet Gynecol 2003;189:1106-13
   PubMed Web of Science ®Google Scholar
• Cornu J-N, Abrams P, Chapple CR, A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management – a systematic review and meta-analysis. Eurol Urol 2012;62:877-90
   PubMed Web of Science ®Google Scholar
• Weiss JP, Zinner NR, Klein BM, Desmopressin orally disintegrating tablet effectively reduces nocturia: results of a randomized, double bling, placebo-controlled trial. Neurourol Urodyn 2012;31:441-7
   PubMed Web of Science ®Google Scholar
• Juul KV, Klein BM, Norgaard JP. Long-term durabililty of the response to desmopressin in female and male nocturia patients. Neurourol Urodyn 2012; [ Epub ahead of print]
   Web of Science ®Google Scholar
• Liu J, Ji H, Zheng W, Gonadal hormone regulation of the renal vasopressin V2 receptor. FASEB J 2008;22:1159
   Google Scholar
• Stachenfeld NS, Splenser AE, Calzone WL, Sex differences in osmotic regulation of AVP and renal sodium handeling. J Appl Physiol 2001;91:1893-901
   PubMed Web of Science ®Google Scholar
• van Lieburg AF, Verdijk MA, Schoute F, Clinical phenotype of nephrogenic diabetes insipitus in females heterozygous for a vasopressin type 2 receptor mutation. Hum Genet 1995;96:70-8
   PubMed Web of Science ®Google Scholar
• Djavan B, Milani S, Davies J, The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eurol Urol Suppl 2005;4:61-8
   Web of Science ®Google Scholar
• Johnson TM II, Jones K, Williford WO, Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003;170:145-8
   PubMed Web of Science ®Google Scholar
• Johnson TM II, Burrows PK, Kusek JW, The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 2007;178:2045-51
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003;92:257-61
   PubMed Web of Science ®Google Scholar
• Koseoglu H, Aslan G, Ozdemir I, Nocturnal polyuria in patients with lower urinary tract symptoms and response to alpha-blocker therapy. Urology 2006;67:1188-92
   PubMed Web of Science ®Google Scholar
• Vallancien G, Emberton M, Alcaraz A, ALF-ONE study group. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int 2008;101:847-52
   PubMed Web of Science ®Google Scholar
• Wein AJ, Dmochowski RR. Strategies for data comparison for drugs used in the treatment of overactive bladder. In: Kreder K, Dmochowski RR, editor. The overactive bladder, evaluation and management. Informa Healthcare, London; 2007. p. 239-52
   Google Scholar
• Ukimura O, Kanazawa M, Fujihara A, Kyoto Prefectural University of Medicine Benign Prostatic Hypertrophy Research Group. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. Int J Urol 2008;15:1049-54
   PubMed Web of Science ®Google Scholar
• Brubaker L, FitzGerald MP. Nocturnal polyuria and nocturia relief in patients treated with solifenacin for overactive bladder symptoms. Int Urogynecol J 2007;18:737-41
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R, Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004;172:1919-24
   PubMed Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR Trial. Eur Urol 2005;48:464-70
   PubMed Web of Science ®Google Scholar
• Vardy MD, Mitcheson HD, Samuels T-A, Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT - a double-blind, placebo-controlled trial. Int J Clin Pract 2009;63:1702-14
   PubMed Web of Science ®Google Scholar
• Rudy D, Cline K, Harris R, Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006;67:275-80
   PubMed Web of Science ®Google Scholar
• Zinner N, Gittelman M, Harris R, Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311-15
   PubMed Web of Science ®Google Scholar
• Johnson TM II, Burgio KL, Redden DT, Effects of behavioral and drug therapy on nocturia in older incontinent women. J Am Geriatr Soc 2005;53:846-50
   PubMed Web of Science ®Google Scholar
• Rackley R, Weiss JP, Rovner ES, Nighttime dosing with tolterodine reduces bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006;67:731-6
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Appell RA, Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. BJU Int 2006;97:1262-6
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Dmochowski R, Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006;68:328-32
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Tubaro A, Clinical efficacy, safety and tolerability of once daily fesoterodine in subjects with overactive bladder. Eur Urol 2007;52:1204-12
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski RR, Sand PK. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007;178:2488-94
   PubMed Web of Science ®Google Scholar
• Herschorn S, Swift S, Guan Z, Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. BJU Int 2010;105:58-66
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Peters KM, Morrow JD, Randomized, double-blind. placebo-controlled trial of flexible dose fesoterodine in subjects with overactive bladder. Urology 2010;75:62-8
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Rovner ES, Tolterodine and Tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. A Randomized Controlled Trial. JAMA 2006;296:2319-28
   PubMed Web of Science ®Google Scholar
• Vaughan CP, Endeshaw Y, Nagamia Z, A multicomponent behavioural and drug intervention for nocturia in elderly men: rationale and pilot results. BJU Int 2009;104:69-74
   PubMed Web of Science ®Google Scholar
• Addla SK, Adeyoju AB, Neilson D, Diclofenac for treatment of nocturia caused by nocturnal polyuria: a prospective, randomised, double-blind, placebo-controlled crossover study. Eur Urol 2006;49:720-5
   PubMed Web of Science ®Google Scholar
• Falahatkar S, Mokhtari G, Pourreza F, Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 2008;72:813-16
   PubMed Web of Science ®Google Scholar
• Kaye M. Nocturia: a blinded, randomized, parallel placebo-controlled self-study of the effect of 5 different sedatives and analgesics. Can Urol Assoc J 2008;2:604-8
   PubMed Web of Science ®Google Scholar
• Drake MJ, Mills IW, Noble JG. Melatonin pharmacotherapy for nocturia in men with benign prostatic enlargement. J Urol 2004;171:1199-202
   PubMed Web of Science ®Google Scholar
• Kalsi V, Apostolidis A, Gonzales G, Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity. Eurol Urol 2008;54:181-7
   PubMed Web of Science ®Google Scholar
• Schulte-Baukloh H, Schobert J, Stolze T, Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis. Neurourol Urodyn 2006;25:110-15
   PubMed Web of Science ®Google Scholar
• Gras J. Mirabegron for the treatment of overactive bladder. Drugs Today (Barc) 2012;48:25-32
   PubMed Web of Science ®Google Scholar
• Viol GW, Grof P, Daigle L. Renal tubular function in patients on long-term lithium therapy. Am J Psychiatry 1975;132:68-70
   PubMed Web of Science ®Google Scholar
• Fitzgerald MP, Litman HJ, Link CL, BACH Survey Investigators. The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. J Urol 2007;177:1385-9
   PubMed Web of Science ®Google Scholar
• Hall SA, Chiu GR, Kaufman DW, Commonly used antihypertensives and lower urinary tract symptoms: results from the Boston Area Community Health (BACH) Survey. BJU Int 2012;109:1676-84
   PubMed Web of Science ®Google Scholar
• Thomas JP, Coles GA, el-Shaboury AH. Nocturia in patients on long-term steroid therapy. Clin Sci 1970;38:415-25
   PubMed Web of Science ®Google Scholar
• Kamel NS, Gammack JK. Insomnia in the elderly: cause, approach, and treatment. Am J Med 2006;119:463-9
   PubMed Web of Science ®Google Scholar